ISPOR - HTA303 Are BSC and Patient-Individual Therapy as Appropriate Comparators Detrimental for AMNOG Benefit Assessment and Price Rebates in Germany?

HTA303 Are BSC and Patient-Individual Therapy as Appropriate Comparators Detrimental for AMNOG Benefit Assessment and Price Rebates in Germany?

Abstract

Authors

A.P. Gunesch J.F. Löpmeier-Röh N. Italia W. Kulp

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now